CN105532646B - 肝细胞保存液及其制备方法和应用 - Google Patents
肝细胞保存液及其制备方法和应用 Download PDFInfo
- Publication number
- CN105532646B CN105532646B CN201610054463.5A CN201610054463A CN105532646B CN 105532646 B CN105532646 B CN 105532646B CN 201610054463 A CN201610054463 A CN 201610054463A CN 105532646 B CN105532646 B CN 105532646B
- Authority
- CN
- China
- Prior art keywords
- cell
- liquid
- liver cell
- amino acid
- preserves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 90
- 210000005229 liver cell Anatomy 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 83
- 239000000872 buffer Substances 0.000 claims abstract description 62
- 229940024606 amino acid Drugs 0.000 claims abstract description 52
- 150000001413 amino acids Chemical class 0.000 claims abstract description 52
- 238000004321 preservation Methods 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000003204 osmotic effect Effects 0.000 claims abstract description 19
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims abstract description 19
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims abstract description 18
- 235000013923 monosodium glutamate Nutrition 0.000 claims abstract description 18
- 239000008354 sodium chloride injection Substances 0.000 claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- 239000008103 glucose Substances 0.000 claims abstract description 14
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 10
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 9
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 9
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 8
- 150000004291 polyenes Chemical class 0.000 claims abstract description 8
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 8
- 239000011718 vitamin C Substances 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- 229960001031 glucose Drugs 0.000 claims abstract description 4
- 235000001727 glucose Nutrition 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 32
- 239000011259 mixed solution Substances 0.000 claims description 18
- 239000011780 sodium chloride Substances 0.000 claims description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 16
- 239000001110 calcium chloride Substances 0.000 claims description 16
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 16
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 16
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 16
- 239000001103 potassium chloride Substances 0.000 claims description 16
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 16
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 16
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 15
- 229930182817 methionine Natural products 0.000 claims description 15
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 229940079827 sodium hydrogen sulfite Drugs 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 5
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 41
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 15
- 235000018977 lysine Nutrition 0.000 description 13
- 235000008521 threonine Nutrition 0.000 description 13
- 235000014393 valine Nutrition 0.000 description 13
- 235000005772 leucine Nutrition 0.000 description 12
- 235000006109 methionine Nutrition 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 150000008543 L-isoleucines Chemical class 0.000 description 9
- 150000008547 L-phenylalanines Chemical class 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 9
- 150000002669 lysines Chemical class 0.000 description 9
- 150000003588 threonines Chemical class 0.000 description 9
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 9
- 150000003680 valines Chemical class 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 9
- 150000002614 leucines Chemical class 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009920 food preservation Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108010032972 Cellfood Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610054463.5A CN105532646B (zh) | 2016-01-27 | 2016-01-27 | 肝细胞保存液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610054463.5A CN105532646B (zh) | 2016-01-27 | 2016-01-27 | 肝细胞保存液及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105532646A CN105532646A (zh) | 2016-05-04 |
CN105532646B true CN105532646B (zh) | 2017-10-13 |
Family
ID=55812649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610054463.5A Active CN105532646B (zh) | 2016-01-27 | 2016-01-27 | 肝细胞保存液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105532646B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109856089A (zh) * | 2018-11-09 | 2019-06-07 | 合肥诺森医学检验有限公司 | 一种细胞保存液的质量检测方法 |
CN111972399B (zh) * | 2020-08-06 | 2021-11-30 | 温州医科大学 | 维持肝细胞活性的保存液 |
CN113383768B (zh) * | 2021-05-22 | 2022-07-05 | 武汉仝干医疗科技股份有限公司 | 一种肝细胞冻存液及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030442A1 (en) * | 1998-11-25 | 2000-06-02 | Abbott Laboratories | Organ preservation solution containing pyruvate |
CN101491238A (zh) * | 2009-03-06 | 2009-07-29 | 李立 | 一种器官保存液 |
CN101919381A (zh) * | 2010-09-06 | 2010-12-22 | 南方医科大学珠江医院 | 一种生物人工肝用肝细胞的保存液及其制备方法 |
WO2013047666A1 (ja) * | 2011-09-29 | 2013-04-04 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
CN103952370A (zh) * | 2014-04-29 | 2014-07-30 | 周平 | 生物人工肝用细胞源的培养液 |
CN104996396A (zh) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | 一种离体肝脏灌注保存液 |
-
2016
- 2016-01-27 CN CN201610054463.5A patent/CN105532646B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030442A1 (en) * | 1998-11-25 | 2000-06-02 | Abbott Laboratories | Organ preservation solution containing pyruvate |
CN101491238A (zh) * | 2009-03-06 | 2009-07-29 | 李立 | 一种器官保存液 |
CN101919381A (zh) * | 2010-09-06 | 2010-12-22 | 南方医科大学珠江医院 | 一种生物人工肝用肝细胞的保存液及其制备方法 |
WO2013047666A1 (ja) * | 2011-09-29 | 2013-04-04 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
CN103952370A (zh) * | 2014-04-29 | 2014-07-30 | 周平 | 生物人工肝用细胞源的培养液 |
CN104996396A (zh) * | 2015-07-27 | 2015-10-28 | 中山大学附属第一医院 | 一种离体肝脏灌注保存液 |
Non-Patent Citations (2)
Title |
---|
供移植肝脏保存液及肝细胞保护剂研究进展;苏志良 等;《临床肝胆病杂志》;20030831;第19卷(第4期);第209-211页 * |
原代乳猪肝细胞低温保存的初步探索;刘鸿凌 等;《肝脏》;20020930;第7卷(第3期);第168-170页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105532646A (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9968663B2 (en) | Erythrocytes containing arginine deiminase | |
Eder et al. | Congenital methemoglobinemia. A clinical and biochemical study of a case | |
EP0456806B1 (en) | Histidine buffered peritoneal dialysis solution | |
CN105532646B (zh) | 肝细胞保存液及其制备方法和应用 | |
KR890002948B1 (ko) | 수액제의 갈변 방지방법 | |
JPH0534337B2 (zh) | ||
CN1200742C (zh) | 用于输注用途的系统和组合物 | |
CN105586379A (zh) | 一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法 | |
CN101164530B (zh) | 含稳定的丙酮酸钠的水溶液及其制法和用途 | |
IE57908B1 (en) | Heat sterilizable storage solution for red blood cells and blood bags containing it | |
CA3217867A1 (en) | Ready-to-use parenteral nutrition formulation | |
CN104622896A (zh) | 一种钠钾镁钙葡萄糖注射液的制备方法 | |
CN107372464A (zh) | 一种维持间充质干细胞活性的运输保存液与制备方法 | |
JPWO2019230973A1 (ja) | 生体材料保存組成物、生体材料の保存方法、生体材料の生産方法、移植材料、および移植方法 | |
WO2023015756A1 (zh) | 一种细胞吸收组合式功能性营养素 | |
CN112516078B (zh) | 吉西他滨单磷酸酯溶液制剂和应用 | |
CN104738743A (zh) | 一种降尿酸肽饮料及其制备方法 | |
CN102138553A (zh) | 一种临床用干细胞保存液 | |
CN104888196A (zh) | 一种稳定的干扰素α多剂量笔注射液 | |
US20240041023A1 (en) | Composition and method of preserving viability of cell in a low temperature | |
CN103565736A (zh) | 一种羟乙基淀粉130醋酸钠林格注射液及其制备方法 | |
RU2541676C1 (ru) | Добавка к корму для рыб | |
CN110237033A (zh) | 一种2,4二硝基苯酚注射液及其制备方法和用途 | |
US20120329734A1 (en) | Mixture and infusion or drink solution | |
CN113383768B (zh) | 一种肝细胞冻存液及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 430206 East Lake high tech Development Zone, Hubei Province, high and new avenue, No. 818, No. Applicant after: WUHAN TOGO MEDITECH Co.,Ltd. Address before: 430206 East Lake high tech Development Zone, Hubei Province, high and new avenue, No. 818, No. Applicant before: WUHAN TOGO BIOTECHNOLOGY CO.,LTD. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hepatocyte preservation solution and its preparation method and Application Effective date of registration: 20220629 Granted publication date: 20171013 Pledgee: Pudong Shanghai Development Bank Limited by Share Ltd. Wuhan branch Pledgor: WUHAN TOGO MEDITECH Co.,Ltd. Registration number: Y2022420000204 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 4th floor, podium building, Gongtou Building, No. 433-505 Chunhui Road, Lingxi Town, Cangnan County, Wenzhou City, Zhejiang Province, 325000 Patentee after: Zhejiang Tonggan Medical Technology Co.,Ltd. Country or region after: China Address before: No. 818, Gaoxin Avenue, Donghu high tech Development Zone, Wuhan, Hubei 430206 Patentee before: WUHAN TOGO MEDITECH Co.,Ltd. Country or region before: China |